Home>Topics>Companies>Quest Diagnostics

Quest Diagnostics DGX

  1. All
  2. Commentary
  3. Headlines
    1. Quest Sees Robust Volume Growth in 1Q; Raising Our Fair Value Estimate

      Commentary

      Thu, 29 Jan 2015

      Quest Diagnostics posted respectable fourth-quarter results ..... liked the structural characteristics of Quest 's narrow moat and anticipate these will ..... Affordable Care Act. Unfortunately, Quest 's improved volume did not translate

    2. Quest in broad deal with CDC for hepatitis analysis

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Laboratory testing company Quest Diagnostics Inc said on Tuesday it had signed a $520,000 agreement with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment of four strains of viral hepatitis.

    3. BRIEF-Genomic Vision delivers new high-throughput genome analyzer to Quest Diagnostics

      Headlines

      Wed, 7 Jan 2015

      * Delivers new high-throughput genome analyzer to Quest Diagnostics

    4. LabCorp Plans for Covance Acquisition; Our Fair Value Estimate Stands

      Commentary

      Mon, 3 Nov 2014

      for the combined company. However, we believe the combined entity will enjoy competitive benefits over key rival Quest Diagnostics , especially over the longer term as the new post-health-care-reform world evolves. We think the strategic

    5. Quest Sees Signs of Improving Business in Third Quarter

      Commentary

      Thu, 23 Oct 2014

      Quest Diagnostics posted respectable third-quarter results ..... suggest volume and pricing are improving for Quest . We stand behind the firm's narrow ..... the moat trend is stable. We applaud Quest 's decision to walk away from unprofitable

    6. Quest Sees Slight Volume Gain in Second Quarter, but Also Faces Price Decline

      Commentary

      Thu, 24 Jul 2014

      Quest Diagnostics released second-quarter performance ..... organic volume growth remains lackluster at Quest . On one hand, quarterly organic volume ..... quarters of declines. On the other hand, Quest continues to trail its main rival LabCorp

    7. Raising Fair Value on Sonic Healthcare to Reflect Growing Offshore Presence

      Commentary

      Wed, 11 Jun 2014

      are reimbursed under Medicare and Medicaid respectively. In the U.S., Sonic remains a minnow compared with Quest Diagnostics and LabCorp, with a market share of about 1.5% versus 15%. The U.S. market remains attractive given expected

    8. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers

      Headlines

      Tue, 3 Jun 2014

      was with Oakmark Equity & Income's elimination of Quest Diagnostics DGX "> DGX . Clyde McGregor noted the following in his ..... and three that didn’t (Encana, Hospira and Quest Diagnostics )... In the case of Encana and Quest Diagnostics

    9. LabCorp's First-Quarter Volume Was Solid, but Pricing Took a Hit

      Commentary

      Mon, 28 Apr 2014

      molecular pathology codes and sequestration. As with Quest Diagnostics , we anticipate the pressure should lift somewhat now ..... believe this sets LabCorp apart from its largest rival Quest . LabCorp is on the cusp of rolling out its Beacon LBS

    10. Quest Diagnostics Posts Anemic 1Q, and Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 24 Apr 2014

      Quest Diagnostics posted tepid first-quarter performance ..... the quarter to change our thinking on Quest 's narrow economic moat. Although the ..... these slightly more positive trends, Quest 's operating margin fell yet again

    « Prev12345Next »
    Content Partners